Your browser doesn't support javascript.
loading
Achievement of a negative minimal residual disease state after hypomethylating agent therapy in older patients with AML reduces the risk of relapse.
Boddu, P; Jorgensen, J; Kantarjian, H; Borthakur, G; Kadia, T; Daver, N; Alvarado, Y; Pemmaraju, N; Bose, P; Naqvi, K; Yilmaz, M; Pierce, S; Brandt, M; DiNardo, C D; Jabbour, E J; Konopleva, M; Garcia-Manero, G; Cortes, J; Ravandi, F.
Afiliação
  • Boddu P; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jorgensen J; Department of Pathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kantarjian H; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Borthakur G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Kadia T; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Daver N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Alvarado Y; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pemmaraju N; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Bose P; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Naqvi K; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yilmaz M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pierce S; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Brandt M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • DiNardo CD; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jabbour EJ; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Konopleva M; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Garcia-Manero G; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cortes J; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Ravandi F; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Leukemia ; 32(1): 241-244, 2018 01.
Article em En | MEDLINE | ID: mdl-28919634
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Neoplasia Residual / Metilação / Antineoplásicos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Ano de publicação: 2018 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Leucemia Mieloide Aguda / Neoplasia Residual / Metilação / Antineoplásicos Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Leukemia Ano de publicação: 2018 Tipo de documento: Article